Accord ing to a recent inter na tional consen sus, a non myeloablative regi men is one which induces mini mal if any cyto penia. 7 The ASSIST regi men is associated with profound cytopenia, 1 and the HSCT is used to reduce this critical period of aplasia. The regimen is therefore better classified as 'reducedintensity conditioning' . 7 The authors were faced with the same pro blem as are all who work in the field of SSc clinical research: which primary end points for trials in SSc are clinically meaning ful? The mRSS can improve with time alone, and is subject to wide inter-observer error; 8 three scorers participated in ASSIST. Similar if not greater improvements in skin pathology have been observed in trials of methotrexate, 9 but it is nevertheless encouraging that ASSIST also showed early improvement in pulmo nary status, perhaps reflecting selection of early cases.
Most importantly, the apparently positive outcome will only be relevant if maintained after longer followup. The field of HSCT is replete with promising early phase I/II reports, in the field of autoimmune dis orders as well as in hematology and oncol ogy, where expectation can drive diffusion of a medical technology more than evidence. Around 30,000 women worldwide were treated with autologous HSCT for breast cancer in the 1990s, on the basis of very promising early data and driven by massive public pressure, before it was abandoned as a futile, toxic treatment. 10 "One swallow does not make a summer. " I hope indeed that the positive message, of acceptable toxicity and a meaningful and durable benefit for patients, of ASSIST will hold, and will be confirmed by the larger ASTIS and SCOT trials. Yet I would caution my patients that this swallow might be flying far ahead of his companions. 
RHEUMATOID ARTHRITIS
Repair of erosion in RA-shifting the balance to formation
Ellen M. Gravallese and Nicole C. Walsh
Repair of bone erosions in rheumatoid arthritis has been considered a difficult goal to achieve. However-with better therapies at hand to control synovial inflammation-sensitive μCT imaging techniques now available confirm that repair of bone erosion is possible, and begins at the base of erosive lesions. The past decade has seen remarkable pro gress in the treatment of rheumatoid arthri tis (RA), accompanied by an increasing interest in the mechanisms responsible for destruction of the articular bone in this disease. Inflammation in the bone micro environment in arthritic conditions such as RA leads to the generation of boneresorbing osteoclasts, and, at the same time, bone for mation by osteoblasts is suppressed, resulting in a net loss of bone and impaired capacity for erosion repair. Nevertheless, despite the use of potent anti inflammatory agents such as TNF inhibitors-which control clinical inflamma tion and specifically block cyto kines that mediate inflamma tion-repair of eroded articular bone seems, perplexingly, to occur infrequently. The explanation for this intriguing clinical observation remains to be fully elucidat ed. A report by Finzel et al. 1 
in
Annals of the Rheumatic Diseases now offers insights into the capacity of tradi tional and biologic therapies to promote repair of ero sions in patients with RA. Their work sug gests that the use of TNF inhibitors moves us in the right direction in fostering bone formation, but complete repair of erosions remains an elusive clinical goal.
Finzel and colleagues used high resolution microcomputed tomography (μCT) scan ning to better evaluate the impact of RA therapy on repair of articular bone. Erosions detec ted in patients undergoing metho trexate therapy alone, or metho trexate plus an anti TNF agent (after a minimum of 3 months of stable treatment), were measured for width and depth at base line and after 1 year of treatment. Using this sensitive μCT tech nique, the authors showed a statistically significant improve ment in the mean depth, but not width, of erosions in patients receiv ing antiTNF therapy. By contrast, ero sions in patients treated with methotrexate alone showed an increase in mean erosion width and depth, indicating progression. Ero sions that showed a reduction in depth were typically deep lesions, characterized by the presence of sclero tic bone either at baseline and/or at followup, indicating that bone repair resulted from new bone for mation on endosteal surfaces at the base of the erosions.
1
These data in patients with RA follow nicely from studies using mouse models of the disease, which examined the impact of inflammation on osteoblast maturation and bone formation in articular erosions. In these studies, bone surfaces adjacent to invad ing inflammatory tissue were found to be characterized by impaired bone formation associated with a paucity of mature osteo blasts, despite the prevalence of immature osteoblastlineage cells lining the endo steal bone surfaces.
2 By contrast, as inflam mation resolved, mature osteo blasts popu lated these surfaces and formed bone, leading to repair of erosions over time. 3 There fore, the degree of local inflammation is likely to be an important factor in de termining erosion repair in RA.
Consistent with these observations, pre vious studies in patients with RA designed to identify repair of erosions by conven tional radiography have demonstrated that erosion repair can occur; 4 however, rates of repair are low. In a small cohort of patients with RA treated with conventional DMARD therapy, Ideguchi et al. 5 demonstrated that repair occurred in approximately 10% of patients. Furthermore, repair was identi fied primarily in those patients with low disease activity, a finding supported in a more recent study of patients treated with conventional therapy. 6 Why might we expect patients receiving antiTNF therapy to experience a better rate of erosion repair than those treated with conventional DMARDs? TNF is a pro inflammatory cytokine that contributes significantly to the inflammatory process in RA. Moreover, TNF has an impact on several mechanisms that are directly involved in the erosive process (Figure 1) : it increases the expression of the key osteoclast differentia tion factor RANKL (receptor activator of nuclear factor κBligand, also known as TNF ligand super family member 11); it expands the pool of osteoclast pre cursor cells; and it can act synergisti cally with RANKL to promote osteoclast differ entiation. 7 In addition to promoting osteoclastogenesis and bone resorption, TNF also acts to inhibit bone formation by suppressing osteoblast matura tion through inhibition of the expres sion of runtrelated transcription factor 2, a trans cription factor critical for osteoblast lineage commitment and gene expression, resulting in reduced bone forma tion and mineraliza tion. 7 Furthermore, TNF can act on synovial fibroblasts from patients with RA to induce the expression of Dickkopf1, an inhibitor of the Wnt signaling pathway. TNF acts in proinflammatory signaling pathways within the joint to contribute to inflammation, and has synergistic effects on bone turnover: it promotes osteoclast-mediated bone erosion by expanding the RANK + osteoclast precursor cell population and promoting expression of RANKL relative to OPG; it inhibits osteoblast maturation and function, in part by increasing expression of the Wnt antagonist DKK1, resulting in impaired bone formation. Abbreviations: DKK1, Dickkopf-1; OPG, osteoprotegerin (also known as TNF receptor superfamily member 11B); RANK, receptor activator of nuclear factor κB; RANKL, RANK ligand.
variety of radiographic techniques were used to assess bone, and which demonstrated improvement in erosions following treatment with an antiTNF agent. 9, 10 Interestingly, in the current study 1 a greater percentage of ero sions showed signs of sclerosis-indicating some degree of ongoing bone formation -at baseline in patients treated with metho trexate alone, compared with patients treated with the addition of an antiTNF agent. This observation might reflect that these patients had less severe disease than those in whom the addition of TNF blockade was required.
Although the study by Finzel et al. 1 is encouraging in that it shows that TNF inhibi tors might be able to reverse erosive damage to a greater degree than has previously been surmised, repair is limited. The μCT scan ning used by the investigators is excellent for quantitation of bone, but it does not allow for assessment of synovial inflammation or of bone marrow edema, as was accomplished in a previous study. 10 Therefore, the question of whether inflamma tion was eradicated at sites of bone erosion that did or did not repair could not be addressed. Additional studies using μCT in conjunction with MRI or sensitive ultrasound techniques that can accurately measure residual synovial inflam mation within individual sites of erosion could address the remaining important question: is repair of erosions directly related www.nature.com/nrrheum NEWS & VIEWS to the ability of therapeutic interventions to strictly control local joint inflammation?
Finally, how important is it in the clinical care of patients with RA that articular bone erosions heal? Strong evidence certainly exists for the correlation of bone erosion and joint damage with functional disability over time in these patients, but we do not yet know the functional implications of erosion repair. Nonetheless, if a direct correlation between local control of inflammation and repair of erosions were to be clearly estab lished in patients, then repair might become an important indicator of therapeutic effi cacy. The use of animal models of RA will be important to further elucidate the molecular pathways that are active at sites of erosion, and that create a local micro environment conducive for bone repair.
In summary, Finzel et al. 1 have clearly shown that repair of bone erosions can occur in patients with RA, and is character ized by formation of new bone at the base of deep erosions. Control of inflammation, which is likely to be key in shifting the balance towards bone formation and facilitating healing of erosions, remains an important clinical goal.
Systemic sclerosis (SSc) is generally accepted as having the highest frequency of casespecific mortality of the connec tive tissue diseases. The causes of death in patients with SSc have changed over time. Before the development of angiotensin converting enzyme (ACE) inhibitors, renal crisis was the most common reason for mortality; however, more recent analyses performed in different countries around the world have suggested that pulmonary fibrosis and pulmonary hyper tension have now become the most frequent causes of SScrelated death.
1,2 The reasons for this shift are numerous: more frequent and effective screening; improved technology to detect internal organ involvement at earlier stages of disease; 3 and the develop ment of novel efficacious therapies. Such therapies include ACE inhibitors in renal crisis, immuno suppressive medications, and drugs for pulmonary hyper tension, as well as the increased use and success of transplantation procedures. Despite these advances, we remain unable to accurately and reliably predict the risk of mortality in an individual patient with newly diagnosed SSc. In their recent publication, Fransen et al. 4 performed a validation study for a simple predictive model of 5year survival in patients with SSc, originally developed in 1999 by Bryan and colleagues. 5 In this commentary we discuss their results in the context of the specific challenges in develop ing and validating prognostic tools for use in SSc, which need to be considered before applying such instruments in the clinic, or when de veloping new predictive models.
Risk prediction rules enable clinicians to interpret medical data for diagnostic, therapeutic and prognostic assessment, by providing the probability of a par ticular outcome, such as 5year mortality. These prognostic models are developed by apply ing statistical techniques to identify com binations of predictor variables that cate gorize a group of patients with a spe cific disease into risk subgroups. Over the past 20 years, changes in healthcare systems and the advent of evidencebased medicine have forced increased attention on to the development of prediction rules that are simple to use, but which are also accurate and robust. The most wellknown example of a patient assessment tool that uses clini cal risk prediction rules is the Framingham Coronary Heart Disease Prediction Score. 6 Methodological standards for the develop ment of prediction rules were proposed by Wasson et al. 7 and were later modi fied by Laupacis and colleagues. 8 Further more, several publications have discussed the
